Ratified by the U.S. Food and Drug Administration "FDA" yesterday, Thursday, on the issuance of new pharmaceutical preparation for the treatment of soft tissue tumors, advanced and type "advanced soft tissue sarcoma", and is used only for patients who have already use chemotherapy.
VENUS FACTOR REVIEW
This starts with the tumor in tissue injury muscle and adipose tissue and soft cancer, then moves to the tissues of the other, a rare disease that affects about 10,000 patients annually in the United States, and based mechanism of action of the new drug to inhibit the process of formation of new blood vessels, and it needs solid tumors or silenced to grow and survive as long as possible.
And defines new product as the and contains the active substance and the manufacturer of the new drug designed in the form of tablets taken by mouth, which is the second time that it will be adopted where, where was ratified in last year, but for the treatment of advanced renal cell carcinoma.
Labs and side effects caused by the new drug, a sense of fatigue, diarrhea, nausea, weight gain, high blood pressure, poor appetite, vomiting, muscle pain, headaches and a change in color of the skin and hair.
Warned patients, doctors and health care centers of the possibility that cause the drug in the incidence of liver cirrhosis, and advised that the subject patients to tests and liver function before and during use, and stop using it immediately in the event of any decline or deterioration in liver enzymes
No comments:
Post a Comment